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Intermittent claudication is the primary symptom of peripheral arterial disease, affecting between 1 and 3 million
Americans. Symptomatic improvement can be achieved by endovascular revascularization, but such procedures are
invasive, expensive, and may be associated with procedural adverse events. Medical treatment options, including
claudication medications and supervised exercise training, are also known to be effective, albeit also with associated
limitations. The CLEVER (Claudication: Exercise Vs. Endoluminal Revascularization) study, funded by the Heart,
Lung, and Blood Institute of the National Institutes of Health, is a prospective, multicenter, randomized, controlled
clinical trial evaluating the relative efficacy, safety, and health economic impact of four treatment strategies for people
with aortoiliac peripheral arterial disease and claudication. The treatment arms are: (1) optimal medical care (claudication
pharmacotherapy); (2) primary stent placement; (3) supervised exercise rehabilitation; and (4) combined stenting with
supervised exercise rehabilitation. The CLEVER study is a 5-year randomized, controlled clinical trial to be conducted at
approximately 25 centers in the United States that will monitor 252 patients and their responses to treatment during a n
18-month follow-up period. The primary end point is change in maximum walking duration on a graded treadmill
test. Secondary end points include the change at 18 months in maximum walking duration from baseline,
comparisons of free-living daily activity levels assessed by pedometer, health-related quality of life, and cost-
effectiveness. Other analyses include the effect of these treatment strategies on anthropomorphic and physiologic
variables, including body mass index, waist circumference, blood pressure, pulse pressure, and resting pulse as well
as biochemical markers of cardiovascular health, including fasting lipids, fibrinogen, C-reactive protein, and
hemoglobin A1c values. ( J Vasc Surg 2008;47:1356-63.)Claudication is the most frequent symptom of periph-
eral arterial disease (PAD)1 and is usually experienced as a
reproducible fatigue, discomfort, or pain in the thigh or calf
muscles that is provoked by walking and2,3 relieved by rest.
All individuals with PAD have functional impairment, but
symptoms of moderate to severe claudication profoundly
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1356limit physical functioning.4 Physical activity is known to be
inversely associated with the incident of cardiovascular isch-
emic events,5 and a lack of physical activity is known to
contribute to obesity, which may further increase cardio-
vascular disease risk.6 Obesity in adults is associated with
walking disability,7 and walking disability caused by claudi-
cation results in a sedentary lifestyle,8 self-perceived ambu-
latory dysfunction,9 and lower health-related quality of
life.10 Moderate to severe claudication usually precludes an
active, healthy lifestyle.
MANAGEMENT OF INTERMITTENT
CLAUDICATION
Treatment of claudication varies, depending on the
severity of presenting symptoms and the associated impact
of this physical disability on individual lifestyle. Patients
with mild to moderate disability from claudication have
traditionally been treated by a regimen of risk factor mod-
ification, smoking cessation, and physician-derived exhor-
tations to exercise. The de facto past standard of care has
been for the physician to advise patients to “stop smoking
and keep walking.”11
The role of revascularization for those with intermit-
tent claudication has been controversial.12,13 Vascular sur-
geons have traditionally reserved lower extremity surgical
bypass for patients with moderate to severe symptoms of
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low operative risk and who are likely to enjoy good, long-
term functional survival. This approach has been based on
the low but significant perioperative cardiovascular mor-
bidity and mortality associated with surgical bypass and the
observation that most patients with claudication do not
progress to limb-threatening ischemia. This therapeutic
paradigm probably reduces procedure-related deaths but
offers minimal symptom relief to most patients.
In recent years, stenting has become one preferred
method to achieve revascularization of occlusive lesions of
the aortoiliac segment and has demonstrated clinical im-
provement in symptoms of claudication in uncontrolled
series.14 Recent advances in percutaneous treatment of
lower extremity PAD have prompted many physicians who
treat claudication to consider more liberal indications for
percutaneous intervention. At the same time, it has been
demonstrated that excellent improvement in maximum
walking distance can also be achieved with supervised exer-
cise therapy,15 with a low risk of disease progression or
amputation,16 without revascularization.12,13
Pharmacologic agents such as cilostazol have been
shown to improve the symptoms of claudication in multi-
ple, randomized, placebo-controlled clinical trials. The ef-
ficacy of supervised exercise and pharmacotherapy and a
lack of evidence that either angioplasty or bypass surgery
are more effective at preventing amputation17 in patients
with claudication has offered a strong rationale that sup-
ports the use of medical management (claudication phar-
macotherapy or supervised exercise, or both) as the first line
of therapy over any form of revascularization in patients
with claudication from PAD. This evidence base and asso-
ciated treatment algorithms have recently been encom-
passed in an inter-societal lower extremity PAD treatment
guideline.18
Numerous clinical trials have demonstrated that super-
vised exercise therapy9,19-23 and claudication medica-
tions24 can significantly improve walking performance and
quality of life in patients with intermittent claudication.15
The first randomized controlled trial of exercise therapy in
PAD patients to demonstrate improvement was completed
in 1966.25 On average, individuals enrolled in supervised
exercise programs improve maximum walking duration
(MWD) between 74% and 240% on a continuous-load
treadmill protocol.26 Most comparisons of supervised ex-
ercise therapy and unsupervised exercise show no improve-
ment,15 or at best modest improvement19 in MWD for
unsupervised exercise. Despite robust proof of therapeutic
efficacy, a major factor that now severely limits access to
supervised exercise rehabilitation for individuals with inter-
mittent claudication is lack of reimbursement by health care
payors.
The relative roles of angioplasty and exercise for pa-
tients with stable PAD and intermittent claudication have
been the subject of a Cochrane Database Review.27 This
review presented data from two studies that randomized
claudication patients to angioplasty or other treatment.
Most patients in these series were treated for femoropopli-teal PAD and revascularized with balloon angioplasty
alone, stents were not used.28,29 The results of the two
randomized trials were discordant at 6 months: the Edin-
burgh study showed the most improvement in walking
distance in the angioplasty group,29 whereas the Oxford
experience showed better results with supervised exer-
cise.30 Notably, the Oxford group used supervised exercise,
which offers better outcomes than home exercise.31 A
subgroup analysis of the Oxford experience, showed better
exercise performance with angioplasty for those with aor-
toiliac PAD at baseline vs femoropopliteal PAD.30
The CLEVER study thus challenges the popular man-
agement paradigm for individuals with intermittent claudi-
cation by directly comparing four differing treatment strat-
egies:
1. a primary medical therapeutic approach; for example,
home exercise with claudication pharmacotherapy, de-
fined as optimal medical care (OMC);
2. OMC plus interventional revascularization;
3. OMC plus supervised exercise; and
4. a previously untested treatment strategy that can pro-
vide insight into the potential synergy of these ap-
proaches, consisting of OMC plus intervention plus
supervised exercise therapy.
POPULATION
The CLEVER study eligibility criteria (Appendix II)
target individuals with intermittent claudication resulting
from ipsilateral lower extremity PAD primarily in the aor-
toiliac segments. Patients whose comorbid conditions sig-
nificantly limit their walking ability are excluded from the
CLEVER study because the study targets patients whose
primary walking impairment is due to claudication resulting
from arterial insufficiency. The only anatomic contraindi-
cations for randomization will be patients who are random-
ized to stent revascularization by noninvasive tests and are
found at angiography to have total aortoiliac obstruction
from the renal arteries to the inguinal ligaments at angiog-
raphy, or those with common femoral artery stenoses or
occlusions. However, any patients with these criteria iden-
tified after randomization will be retained in their assigned
treatment group and will be analyzed in their intention-to-
treat cohort.
TREATMENT GROUPS
The CLEVER study has four treatment groups: OMC,
intervention/stent (ST), supervised exercise (SE), and ST
combined with SE (STSE). All CLEVER study partici-
pants will receive (1) PAD-specific recommendations for
risk factor management, including advice on diet and
home-based exercise, and (2) the claudication medication
cilostazol (Pletal, Otsuka America Pharmaceuticals, Rock-
ville, Md), without charge, for the duration of the study.
The SE group will enroll in a supervised exercise train-
ing program for 26 weeks, consisting of 3 sessions per week
at a designated training center, with sessions 1 hour long.
The baseline workload and subsequent increases in work-
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previously described.32 Supervised exercise performance
including improvement in performance will be centrally
monitored with triggers identified to indicate advancement
of exercise prescription and to optimize treatment delivery.
An Exercise Training Committee consisting of seven mem-
bers will interact with sites directly before and during training
of each participant enrolled in an SE group. Furthermore, a
personal health educatorwill deliver a telephone-based behav-
ioral intervention designed to maintain exercise from months
7 through 18 after the supervised exercise ends for this group.
Patients randomized to the ST group will receive OMC
care and stent revascularization of aortoiliac and above knee
femoropopliteal atherosclerotic stenoses.
The STSE group is designed to explore the relative
additive benefit of the supervised exercise program on
physical functioning for individuals who also undergo stent
placement. This strategy has intuitive appeal, although no
data regarding this combined approach have been pub-
lished. The analysis of this group will be “hypothesis-
generating” because this study is not powered to evaluate
the potential synergy between supervised exercise therapy
and stent placement in the primary analysis.
CARDIOVASCULAR RISK FACTOR
MANAGEMENT AND BACKGROUND
THERAPY
All treatment arms in CLEVER will receive specific
recommendations to achieve risk factor modification to
specific guideline-derived targets to reduce their risk of
cardiovascular ischemic events. The CLEVER investigators
have adopted current treatment recommendations to facil-
itate success for each randomized subject, regardless of
treatment assignment, to achieve smoking cessation, lipid
and blood pressure management, and diabetes control. In
addition, all patients will receive educational materials de-
signed to foster community-based exercise and, if renal
function is normal, information about the Dietary Ap-
proaches to Stop Hypertension (DASH) Eating Plan.33
Active engagement of risk factor therapy and background
medical therapy for each subject at every study site has
rarely been a component of prior claudication clinical trials.
END POINTS
The primary end point of the CLEVER study is change
in MWD on a graded treadmill test (Gardner protocol)
from baseline to 6 months, which is the total duration of
the supervised exercise treatment. After supervised exercise
ends, a behavioral medicine programwill start and continue
for 12 more months. Then, comparisons of change in
MWD from baseline will be repeated at 18 months to
evaluate the durability of both stent and supervised exercise
results. Other secondary end points to be evaluated at both
6 and 18 months include comparisons of free-living daily
activity levels using pedometer readings, health-related
quality of life as assessed by the Medical Outcome Study
Short-Form 12-Item Health Survey (SF-12), the Walking
Impairment Questionnaire, and the Peripheral ArteryQuestionnaire; cost-effectiveness; effect of treatments on
diverse cardiovascular risk factors such as body mass index
(BMI), waist circumference, blood pressure, pulse pressure,
resting pulse, and biochemical markers such as fasting
lipids, fibrinogen, C-reactive protein, and hemoglobin A1c;
and examination of subgroup interactions.
HYPOTHESIS TESTING AND
RANDOMIZATION
The primary aim of the study is to compare the relative
effect of the three arms (OMC, OMCST, and
OMCSE) on improvement of MWD, measured as the
change in MWD between baseline and 6 months after
randomization. The study is powered to detect a 30%
difference in the change in MWD for stent vs supervised
exercise treatments.4 Although the stent vs supervised ex-
ercise comparison is of primary interest, there are limited
data demonstrating that either of these treatments is supe-
rior to optimal medical care. Therefore, CLEVER is de-
signed to test whether each of these interventional thera-
pies is superior to OMC before comparing them with each
other. This sequential analysis plan will preserve the desired
  .05 for the primary comparison of interest.
Assuming a baseline mean MWD of 5 minutes and a
125% increase in MWD after supervised exercise,9,31,32 a
sample size of 63 patients for each of the ST and SE groups
yields 80% power to detect a 30% treatment difference in
mean change from baseline using a two-sided .05 level of
significance. CLEVER will enroll 84 patients in each of
these group to account for subject loss to follow-up. As-
suming a 60% improvement inMWDbetween baseline and
6 months for the OMC group, 37 OMC patients provide
99% and 98% power to detect a 30% relative improvement
for each of OMCST and OMCSE groups, respectively,
using a one-sided .025 level of significance for each com-
parison. CLEVER will enroll 42 patients to provide 37 for
analysis.
In addition to the three study arm comparisons, there is
also interest in a possible additive effect of combined ther-
apy with stenting and supervised exercise compared with
stenting alone. CLEVER will randomize 42 such patients
to evaluate this secondary hypothesis.
To achieve the desired unequal sample sizes, random-
ization will be performed according to the scheme in Fig 1.
Pair-wise analyses of covariance will be used to assess the
significance of the difference between (1) stent vs medical
care, (2) supervised exercise vs medical care, and (3) super-
vised exercise vs stent on the change from baselineMWD at
6 months (Fig 2). Each pair-wise contrast will be evaluated
one at a time in the order above, using analysis of covari-
ance, adjusting for baseline MWD, baseline cilostazol use,
and study center (Fig 3).
A NOVEL APPROACH TO CLAUDICATION
CLINICAL INVESTIGATION
CLEVER should provide a database that can inform
many aspects that underpin the choice of treatment strategy
for individuals with claudication. First, the relative efficacy
edica
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real world multicenter clinical trial, as well as assessment of
a new combined therapy, stent combined with supervised
exercise, which could be the optimal treatment for this
disease by providing local as well as systemic therapy.
Second, these data should, beyond defining the impact
of these therapies on treadmill-based exercise performance,
also define the effect of these treatments on subjective
quality of life, community-based walking, and potentially
other surrogate markers of ischemic cardiovascular disease
risk. CLEVER may elucidate differential impacts among
treatments in important population subgroups, for exam-
Fig 1. Treatment allocation plan for the Claudication:
subjects. All treatment groups are included in optimal m
Fig 2. Statistical analysis plan for the Claudication: E
OMC, optimal medical care.ple, by age, sex, or ethnicity. Claudication treatment deci-sions are complex and offer distinct balances of effects on
short-term and long-term individual and public health, and
the CLEVER database should permit these decisions to be
made with greater precision to optimize patient outcomes.
CONCLUSIONS
New cardiovascular therapeutic technologies and med-
ications may be approved and then rapidly disseminate into
clinical practice without rigorous evaluation of their relative
benefit and risk. For individuals with PAD and claudica-
tion, small, single-center, randomized clinical trials have
offered inconsistent results and do not fully inform these
ise Vs. Endoluminal Revascularization (CLEVER) trial
l care.
e Vs. Endoluminal Revascularization (CLEVER) trial.Exercxercispatients and their clinicians about the relative efficacy and
ised
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treatments. The current high prevalence of claudication
and its anticipated increase in our aging population man-
date that prospective clinical trials continue to measure the
potential benefit, risk, and health economic impact of each
potential strategy on management of this common cardio-
vascular disease. The CLEVER trial, sponsored by the
National Heart, Lung, and Blood Institute of the National
Institutes of Health, is currently enrolling subjects and
provides a unique opportunity to test both established and
emerging strategies of care for individuals with PAD and
claudication.
AUTHOR CONTRIBUTIONS
Conception and design: TM, AH, JJR, DEC, EM, JGR,
AC, DJC
Analysis and interpretation: DEC
Data collection: AH, DEC
Writing the article: TM, AH, JJR, DEC, EM, JGR, AC,
DJC
Critical revision of the article: TM, AH, JJR, DEC, EM,
JGR, AC, DJC
Final approval of the article: TM, AH, JJR, DEC, EM,
JGR, AC, DJC
Statistical analysis: TM, AH, DEC
Obtained funding: TM, AH, DEC
Overall responsibility: TM
REFERENCES
1. Ouriel K. Peripheral arterial disease. Lancet 2001; 358:1257-64.
2. Hiatt WR,Marshall JA, Baxter J, Sandoval R, HildebrandtW, Kahn LR,
et al. Diagnostic methods for peripheral arterial disease in the San Luis
Valley Diabetes Study. J Clin Epidemiol 1990;43:597-606.
3. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and
mortality in hypertensive adults with a low ankle/arm blood pressure
Fig 3. Timeline and study design of the Claudication: E
ABI, Ankle-brachial index; ETT, exercise treadmill test
cardiovascular events; MAPE, major adverse peripheral
transluminal angioplasty; QOL, quality of life; SE, supervindex. JAMA 1993;270:487-9.4. McDermottMM,Greenland P, Liu K, Guralnik JM, CriquiMH,Dolan
NC, et al. Leg symptoms in peripheral arterial disease: associated clinical
characteristics and functional impairment. JAMA 2001;286:1599-606.
5. TanasescuM, LeitzmannMF, RimmEB,Willett WC, StampferMJ, Hu
FB. Exercise type and intensity in relation to coronary heart disease in
men. JAMA 2002;288:1994-2000.
6. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of
life lost due to obesity. JAMA 2003;289:187-93.
7. Weil E,WachtermanM,McCarthy EP, Davis RB, O’Day B, Iezzoni LI, et
al. Obesity among adults with disabling conditions. JAMA 2002;288:
1265-8.
8. Sieminski DJ, Gardner AW. The relationship between free-living daily
physical activity and the severity of peripheral arterial occlusive disease.
Vasc Med 1997;2:286-91.
9. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves
functional status in patients with peripheral arterial disease. J Vasc Surg
1996;23:104-15.
10. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. Effect
of lower extremity blood pressure on physical functioning in patients who
have intermittent claudication. The Chicago Claudication Outcomes Re-
search Group. J Vasc Surg 1996;24:503-11; discussion 511-2.
11. Housley E. Treating claudication in five words. Br Med J (Clin Res Ed)
1988;296:1483-4.
12. Coffman JD. Intermittent claudication--be conservative. N Engl J Med
1991;325:577-8.
13. Hertzer NR. The natural history of peripheral vascular disease. Impli-
cations for its management. Circulation 1991;83:I12-9.
14. Murphy TP, Soares GM, Kim HM, Ahn SH, Haas RA. Quality of life
and exercise performance after aortoiliac stent placement for claudica-
tion. J Vasc Interv Radiol 2005;16:947-53; quiz 954.
15. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training
for claudication. N Engl J Med 2002;347:1941-51.
16. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen
KH, Schroeder T. Fate in intermittent claudication: outcome and risk
factors. Br Med J (Clin Res Ed) 1986;293:1137-40.
17. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass
surgery, and amputation in the management of peripheral vascular
disease. N Engl J Med 1991;325:556-62.
18. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin
JL, et al. ACC/AHA 2005 Practice Guidelines for the management of
patients with peripheral arterial disease (lower extremity, renal, mesen-
teric, and abdominal aortic): a collaborative report from the American
ise Vs. Endoluminal Revascularization (CLEVER) trial.
D, maximum walking distance; MACE, major adverse
s; PAD, peripheral arterial disease; PTA, percutaneous
exercise; Th-BI, thigh-brachial index.xerc
; MW
eventAssociation for Vascular Surgery/Society for Vascular Surgery, Society
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 6 Murphy et al 1361for Cardiovascular Angiography and Interventions, Society for Vascular
Medicine and Biology, Society of Interventional Radiology, and the
ACC/AHA Task Force on Practice Guidelines (Writing Committee to
Develop Guidelines for the Management of Patients With Peripheral
Arterial Disease): endorsed by the American Association of Cardiovascular
andPulmonaryRehabilitation;NationalHeart, Lung, andBlood Institute;
Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and
Vascular Disease Foundation. Circulation 2006;113:e463-654.
19. Savage P, Ricci MA, Lynn M, Gardner A, Knight S, Brochu M, et al.
Effects of home versus supervised exercise for patients with intermittent
claudication. J Cardiopulm Rehabil 2001;21:152-7.
20. Patterson RB, Pinto B, Marcus B, Colucci A, Braun T, Roberts M.
Value of a supervised exercise program for the therapy of arterial
claudication. J Vasc Surg 1997;25:312-8; discussion 318-9.
21. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC,
Flinn WR, et al. Exercise rehabilitation improves functional outcomes
and peripheral circulation in patients with intermittent claudication: a
randomized controlled trial. J Am Geriatr Soc 2001;49:755-62.
22. Ekroth R, Dahllof AG, Gundevall B, Holm J, Schersten T. Physical
training of patients with intermittent claudication: indications, meth-
ods, and results. Surgery 1978;84:640-3.
23. Clifford PC,Davies PW,Hayne JA, BairdRN. Intermittent claudication: is
a supervised exercise class worth while? Br Med J 1980;280:1503-5.
24. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey
EB, et al. A new pharmacological treatment for intermittent claudica-
tion: results of a randomized, multicenter trial. Arch Intern Med
1999;159:2041-50.
25. LarsenOA, LassenNA. Effect of daily muscular exercise in patients with
intermittent claudication. Lancet 1966;2:1093-6.
26. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication.
Cochrane Database Syst Rev 2000;CD000990.
27. Fowkes FG, Gillespie IN. Angioplasty (versus non surgical manage-
ment) for intermittent claudication. Cochrane Database Syst Rev 2000;
CD000017.
28. Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise
training versus angioplasty for stable claudication. Long and medium
term results of a prospective, randomised trial. Eur J Vasc Endovasc
Surg 1996;11:409-13.
29. Whyman MR, Fowkes FG, Kerracher EM, Gillespie IN, Lee AJ, Hou-
sley E, et al. Is intermittent claudication improved by percutaneous
transluminal angioplasty? A randomized controlled trial J Vasc Surg
1997;26:551-7.
30. Creasy TS, Fletcher EW. Angioplasty for intermittent claudication. Clin
Radiol 1991;43:81-3.
31. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR.
Hospital vs home-based exercise rehabilitation for patients with periph-
eral arterial occlusive disease. Angiology 1997;48:291-300.32. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP.
Benefit of exercise conditioning for patients with peripheral arterial
disease. Circulation 1990;81:602-9.
33. Anonymous. The DASH Eating Plan. NIH Publication No. 06-4082.
National Institutes of Health, US Department of Health and Human
Services, Bethesda, MD. Available at http://www.nhlbi.nih.gov/
health/public/heart/hbp/dash/new_dash.pdf. Accessed: Mar 30
2007. National Heart, Lung, and Blood Institute. 2006: Abstract.
Submitted Oct 2, 2007; accepted Dec 26, 2007.
APPENDIX I
Clever Steering Committee
Timothy P. Murphy, MD, Rhode Island Hospital Vas-
cular Disease Research Center and Brown Medical School
Department of Diagnostic Imaging, Providence, RI; Alan
T. Hirsch, MD, University of Minnesota, and the Minne-
apolis Heart Institute Foundation, Minneapolis, Minn;
John J. Ricotta, MD, Stony Brook University Hospital,
Stony Brook, NY; Donald E. Cutlip, MD, Beth-Israel
Deaconess Medical Center, Boston, Mass; Emile Mohler,
MD, the University of Pennsylvania, Philadelphia, Pa; Ju-
dith G. Regensteiner, PhD, the University of Colorado
Health Sciences Center, Denver, Colo; Anthony J. Com-
erota, MD, the Toledo Hospital, Toledo, Ohio; David J.
Cohen, MD, MSc, Saint Luke’s MidAmerica Heart Insti-
tute, Kansas City, Mo; Joseph Massaro, PhD, Boston
University School of Public Health, Boston, Mass; Beth
A. Lewis, PhD, School of Kinesiology, Joselyn Cerezo,
MD, the Division of Epidemiology and Community
Health, School of Public Health, and Michael W. Steffes,
MD, PhD, Department of Laboratory Medicine and
Pathology, University of Minnesota, Minneapolis, Minn;
Michael R. Jaff, DO, Massachusetts General Hospital
and Harvard Medical School, Boston, Mass; George
Sopko, MD, Suzanne H. Goldberg, MSN, and Abby G.
Ershow, ScD, the National Heart, Lung, and Blood
Institute, National Institutes of Health, Bethesda, Md;
Niki U. Cotton-Oldenburg, MPH, DrPH, the Minne-
apolis Heart Institute Foundation, Minneapolis, Minn.APPENDIX II
Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study eligibility criteria
Scoring of the San Diego Claudication Questionnaire for CLEVER eligibility is unique to this study and explained
in the protocol. All duplex ultrasound, magnetic resonance angiography (MRA), and computed tomography
angiography (CTA) images are submitted to the duplex core lab or Clinical Coordinating Center for over read.
Table 1. CLEVER Study Eligibility Criteria. Scoring of the San Diego Claudication Questionnaire for CLEVER
eligibility is unique to this study and explained in the protocol. All duplex ultrasound, MRA and CTA images are
submitted to the duplex core lab or Clinical Coordinating Center for over read.
Inclusion Criteria
1. Subject has symptoms suggestive of intermittent claudication, such as exercise-induced pain, cramps, fatigue, or other equivalent
discomfort, involving large muscle groups of the leg(s) (calf, thigh, buttocks), relieved by rest.
2. Subject is  40 years old.
3. Claudication score consistent with “Rose”, “atypical”, or “noncalf” claudication by San Diego Claudication Questionnaire.
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a. Contrast Arteriography: Contrast arteriogram showing at least 50% stenosis in the aorta, common iliac artery, or external iliac
artery, OR
b. CTA or MRA: Ankle-brachial index 0.9 (or abnormal ankle PVR waveform at ankle if arteries are incompressible*) with at
least 60% stenosis in the aorta, common iliac artery, external iliac artery, accompanied by a biphasic or monophasic Doppler wave
form at the common femoral artery (loss of early diastolic flow reversal or loss of forward flow during diastole), OR
c. Duplex Ultrasound: Ankle-brachial index 0.9 (or abnormal ankle PVR waveform at ankle if arteries are incompressible*) with
occlusion or focal doubling of peak systolic velocity in the aorta, common iliac artery, or external iliac artery, accompanied by a
biphasic or monophasic Doppler wave form at the common femoral artery (loss of early diastolic flow reversal or loss of forward
flow during diastole), OR
d. Vascular Noninvasive Physiologic Tests: Ankle-brachial index 0.9 (or abnormal ankle PVR waveform at ankle if arteries are
incompressible*) with resting thigh-brachial index (thigh-BI)  1.1, and common femoral artery Doppler systolic acceleration
time 140 msec.
*Abnormal PVR waveform must lack augmentation at the ankle, have a delayed, rounded systolic peak, and straight or convex
downslope, and must be reviewed by the core lab.
Note: MRA/CTA, and contrast arteriogram images images must be submitted to the Clinical Coordinating Center and Doppler
waveform tracings to the Noninvasive Test Committee for over read pre- or post-randomization.
5. Highest ankle pressure reduced by at least 25 mm Hg after exercise compared to resting pressure (or loss of previously present
Doppler signal for both the posterior tibial and anterior tibial arteries immediately after exercise if arteries were incompressible).
Note: The highest ankle pressure result is determined by using the higher result of either the dorsalis pedis or posterior tibial artery
measurement.
6. Subject has moderate to severe claudication symptoms, defined as less than 11 minutes MWD at baseline (initial) Gardner treadmill
test.
7. Performance on a second Gardner treadmill test was within 25% of the initial baseline MWD test result.
Exclusion Criteria
1. Presence of critical limb ischemia (Rutherford Grade II or III59 PAD, defined as pain at rest, ischemic ulceration, gangrene) or
acute limb ischemia (pain, pallor, pulselessness, paresthesias, paralysis) in either leg.
2. Common femoral artery (CFA) occlusion or 50% stenosis by angiography, MRA, CTA, or duplex ultrasound or doubling of
systolic velocity in the ipsilateral common femoral artery by duplex ultrasound, or 50% diameter stenosis by visual estimate in the
CFA by angiography, MRA, or CTA, (inadequate outflow for iliac stent intervention), if available pre-randomization.
3. Known total aortoiliac occlusion from the renal arteries to the inguinal ligaments (all other occlusions, including aortic occlusion,
ARE eligible).
4. Participant has bilateral claudication symptoms and the limb that is more symptomatic does not show evidence of aortoiliac insuffi-
ciency as described in inclusion criterion number 5.
5. Participant has bilateral claudication symptoms, but both limbs are equally symptomatic and one side does not show evidence of
aortoiliac insufficiency as described in inclusion criterion number 5.
6. Subject meets the following exclusions based upon modified American College of Sports Medicine criteria for exercise training:
i. Ambulation limited by co-morbid condition other than claudication, for example:
1. severe coronary artery disease
2. angina pectoris
3. chronic lung disease
4. neurological disorder such as hemiparesis
5. arthritis, or other musculoskeletal conditions including amputation
ii. Poorly-controlled hypertension (SBP180 mm Hg)
iii. Poorly-controlled diabetes mellitus
iv. Other active significant medical problems such as cancer, known chronic renal disease (serum creatinine 2.0 mg/dl within 60
days or renal replacement therapy), known chronic liver disease or anemia, active substance abuse, or known history of demen-
tia.
7. Contraindication to exercise testing according to AHA/ACC guideline, specifically: Acute myocardial infarction (within 3-5 days),
unstable angina, uncontrolled cardiac arrhythmias causing symptoms or hemodynamic compromise, active endocarditis, symptom-
atic severe aortic stenosis, acute pulmonary embolus or pulmonary infarction, acute noncardiac disorder that may affect exercise
performance or be aggravated by exercise such as infection, thyrotoxicosis, acute myocarditis or pericarditis, known physical disabil-
ity that would preclude safe and adequate test performance, known thrombosis of the lower extremity, known left main coronary
stenosis or its equivalent, moderate stenotic valvular heart disease, electrolyte abnormalities, known pulmonary hypertension, tachy-
arrhythmias or bradyarrhythmias, hypertrophic cardiomyopathy, mental impairment leading to inability to cooperate, or high de-
gree atrioventricular block.
8. Arterial insufficiency of target lesion due to restenosis of an angioplasty/stent or bypass is not eligible.
9. Recent (3 months) infrainguinal revascularization (surgery or endovascular intervention).
10. Recent major surgery in the last 3 months.
11. Abdominal aortic aneurysm  4 cm or iliac artery aneurysm 1.5 cm is present.
12. Patients who are pregnant, planning to become pregnant, or lactating.
13. Unwilling or unable to attend regular (3 times a week) supervised exercise sessions.
14. Weight 350 lbs or 159 kg (may exceed treadmill and angiography table limits).
15. Language barrier exists for primary QoL instruments (available in English and Spanish).
16. Inability to understand and sign informed consent forms due to cognitive or language barriers (interpreter permitted).
17. Absolute contraindication to iodinated contrast due to prior near-fatal anaphylactoid reaction (laryngospasm, bronchospasm, car-
diorespiratory collapse, or equivalent) and which would preclude patient from participation in angiographic procedures.
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Volume 47, Number 6 Murphy et al 136318. Allergy to stainless steel or nitinol.
19. Allergy or other intolerance to cilostazol (bleeding history) or history of congestive heart failure [if ejection fraction is shown to be
50% patient may be enrolled].
20. Nonatherosclerotic cause of PAD (fibromuscular dysplasia, dissection, trauma, etc).
21. Inability to walk on a treadmill without grade at a speed of at least 2 mph for at least 2 minutes on the first treadmill test.
22. ST-segment depression 1 mm in any of the standard 12 ECG leads or sustained (30 seconds) arrhythmia other than tachycar-
dia or occasional premature atrial or ventricular contractions during exercise testing.
23. Post-exercise systolic blood pressure within the first five minutes after eligibility treadmill test lower than pre-exercise systolic blood
pressure.
24. A peak heart rate 80% of maximum (calculated by subtracting age from 220) while reporting “onset“ of claudication symptoms
(level 3 or 4) during the second baseline examination.
25. Repeat treadmill test shows a MWD result that is 25% different than the subject’s initial Gardner treadmill test result.Current
active involvement in a supervised exercise program (e.g., with a trainer, exercise protocol, and goals, such as in cardiac or pulmo-
nary rehabilitation) for more than 2 weeks within the prior 6 weeks.APPENDIX
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